Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TP-164
- Development stage
- Unknown
- Lead developer
- TechnoPhage
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
TP-164 is a bacteriophage therapy developed by TechnoPhage for the treatment of infectious diseases, specifically targeting urinary tract infections. As a bacteriophage-based product, its mechanism involves the use of viruses (bacteriophages) that infect and lyse specific bacterial pathogens responsible for urinary tract infections. The drug is currently in the discovery phase and has not yet entered clinical trials or received regulatory approval[1][2][6].
Beyond the preview
Go deeper on TP-164.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TP-164.